GEN Exclusives

More »

GEN News Highlights

More »
Apr 10, 2008

Merck & Co. In-Licenses Cancer Targets from Celera to Develop RNAi Drugs

  • Celera has agreed to provide Merck & Co. with access to up to 10 cancer targets for the development of RNAi-based therapeutics.

    Under the terms of the two-year exclusive license agreement, Celera will receive a license fee, success-based milestones, plus royalties. Merck has the option to extend the exclusivity period or add additional targets. Celera will be able to develop and commercialize related companion diagnostics.

    The targets covered in this agreement are overexpressed on the surface of several different tumor cell types, according to Celera. They were identified with the firm’s proteomics discovery platform.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Cancer Drug Approvals and Efficacy

Do you think regulatory agencies should be required to provide stronger evidence of the clinical effectiveness of cancer drugs, including a greater emphasis on patient survival time?

More »